The RegNet model effectively predicts TERT promoter mutation status from routine MRI, offering a non-invasive tool for preoperative molecular subtyping of glioma. This approach may facilitate personalized treatment planning and address limitations of invasive tissue-based diagnostics. Further validation with multi-center data is warranted to enhance clinical applicability.
Zhu et al. (Thu,) studied this question.